Cancer/Tumor Profiling Market by Technology, Biomarker Type, Cancer Type, Application

List of Tables

The Cancer/Tumor Profiling Market was valued at USD 10.79 billion in 2023, expected to reach USD 12.77 billion in 2024, and is projected to grow at a CAGR of 18.74%, to USD 35.94 billion by 2030.

Cancer/tumor profiling encompasses a comprehensive analysis of the cancerous cells at a genetic and molecular level, which aids in understanding the complexities of tumor heterogeneity and facilitates personalized treatment strategies. The necessity of cancer profiling arises from its critical role in precision medicine, enabling oncologists to tailor treatments based on individual biomarkers, thus improving therapeutic outcomes and minimizing adverse effects. Its applications span across clinical diagnostics, drug discovery, and oncology research, with end-users comprising hospitals, diagnostic laboratories, research institutes, and pharmaceutical companies. Market growth is primarily driven by the increasing prevalence of cancer, advancements in profiling technologies such as next-generation sequencing (NGS), and heightened demand for personalized medicine. Particularly, the shift towards high-throughput technologies and the development of cost-effective profiling methods present vast opportunities for industry expansion. Additionally, partnerships between pharmaceutical firms and technology developers to enhance targeted therapies could fuel market growth. However, challenges such as high costs associated with advanced sequencing platforms, data privacy concerns, and a dearth of skilled professionals act as significant hindrances. Furthermore, regulatory complexities and reimbursement issues pose additional barriers. Potential areas of innovation lie in the development of integrated bioinformatics solutions and AI-driven analytics to enhance data interpretation and predictive modeling. Expanding R&D efforts in liquid biopsy and non-invasive profiling methods could open new vistas for investors and developers alike. The market is dynamic and evolving, with a trend towards cross-disciplinary collaboration to leverage comprehensive datasets for robust clinical insights. To capitalize on emerging opportunities, stakeholders should focus on enhancing the accessibility and affordability of profiling techniques, building strategic alliances, and investing in workforce training programs to bridge the skill gap. Sustainable growth could be realized by fostering innovations that align with global regulatory standards and meet the diverse needs of the oncology treatment landscape.

KEY MARKET STATISTICS
Base Year [2023]	USD 10.79 billion
Estimated Year [2024]	USD 12.77 billion
Forecast Year [2030]	USD 35.94 billion
CAGR (%)	18.74%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer/Tumor Profiling Market

The Cancer/Tumor Profiling Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing adoption of biomarkers to treat cancer patients
- Availability of government and global organizations' initiatives for devising cancer diagnosing methods
- Surging preference for personalized medicines for cancer treatment
Market Restraints
- High capital investment in cancer/tumor profiling instruments and services
Market Opportunities
- Emergence of next-generation sequencing and advancements in tumor profiling
- Improvements in point-of-care diagnostic technologies to improve cancer detection
Market Challenges
- Low biomarker discovery-to-approval ratio

Porter's Five Forces: A Strategic Tool for Navigating the Cancer/Tumor Profiling Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer/Tumor Profiling Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer/Tumor Profiling Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer/Tumor Profiling Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer/Tumor Profiling Market

A detailed market share analysis in the Cancer/Tumor Profiling Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer/Tumor Profiling Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer/Tumor Profiling Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Nonacus Limited, GenScript Biotech Corporation, Tempus Labs Inc., Thermo Fisher Scientific Inc., Hologic, Inc., 4basecare Onco Solutions Private Limited, Personalis, Inc., Merck KGaA, Exact Sciences Corporation, Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Guardant Health, Inc., Sysmex Corporation, Agendia, Inc., Paragon Genomics, Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc., NanoString Technologies, Inc., Predictive Oncology Inc., IMBdx, Inc., Perthera, Inc., GENINUS Inc., Genomic Life, ACT Genomics Co., Ltd. by Prenetics Global Limited, BostonGene Corporation, Caris Life Sciences, Strand Life Sciences, Neogenomics, Inc., Agilent Technologies, Inc., Oncompass Medicine Hungary Kft., and OncoDNA S.A..

Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Technology, market is studied across Immunoassays, In-Situ Hybridization, Mass Spectrometry, Microarrays, Next-Generation Sequencing, and Polymerase Chain Reaction.
Based on Biomarker Type, market is studied across Genomic Biomarker and Protein Biomarker.
Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma Cancer, and Prostate Cancer.
Based on Application, market is studied across Biomarker Discovery, Clinical Application, Diagnostics, Personalized Medicine, Prognostics, Research, Screening, and Treatment & Monitoring.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-374DB5A06C7F

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing adoption of biomarkers to treat cancer patients
  - 5.1.1.2. Availability of government and global organizations' initiatives for devising cancer diagnosing methods
  - 5.1.1.3. Surging preference for personalized medicines for cancer treatment
- 5.1.2. Restraints
  - 5.1.2.1. High capital investment in cancer/tumor profiling instruments and services
- 5.1.3. Opportunities
  - 5.1.3.1. Emergence of next-generation sequencing and advancements in tumor profiling
  - 5.1.3.2. Improvements in point-of-care diagnostic technologies to improve cancer detection
- 5.1.4. Challenges
  - 5.1.4.1. Low biomarker discovery-to-approval ratio
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers
- 5.2.2. Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation
- 5.2.3. Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification
- 5.2.4. Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Cancer/Tumor Profiling Market, by Technology

6.1. Introduction
6.2. Immunoassays
6.3. In-Situ Hybridization
6.4. Mass Spectrometry
6.5. Microarrays
6.6. Next-Generation Sequencing
6.7. Polymerase Chain Reaction

7. Cancer/Tumor Profiling Market, by Biomarker Type

7.1. Introduction
7.2. Genomic Biomarker
7.3. Protein Biomarker

8. Cancer/Tumor Profiling Market, by Cancer Type

8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Lung Cancer
8.5. Melanoma Cancer
8.6. Prostate Cancer

9. Cancer/Tumor Profiling Market, by Application

9.1. Introduction
9.2. Biomarker Discovery
9.3. Clinical Application
9.4. Diagnostics
9.5. Personalized Medicine
9.6. Prognostics
9.7. Research
9.8. Screening
9.9. Treatment & Monitoring

10. Americas Cancer/Tumor Profiling Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cancer/Tumor Profiling Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cancer/Tumor Profiling Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers
- 13.3.2. Sophia Genetics, Agilent Partner on Cancer Analysis Product
- 13.3.3. Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
- 13.3.4. Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
- 13.3.5. Exact Sciences Launches OncoExTra Cancer Therapy Selection Test in the U.S.
- 13.3.6. Caris Life Sciences nears USD 2B in total funding with USD 400M haul
- 13.3.7. Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco
- 13.3.8. Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- 13.3.9. Prenetics Acquires ACT Genomics
- 13.3.10. Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for Enhertu
- 13.3.11. CDC Awards USD 215 Million to Advance Cancer Moonshot Goals

Companies Mentioned

1. Takara Bio Inc.
2. Nonacus Limited
3. GenScript Biotech Corporation
4. Tempus Labs Inc.
5. Thermo Fisher Scientific Inc.
6. Hologic, Inc.
7. 4basecare Onco Solutions Private Limited
8. Personalis, Inc.
9. Merck KGaA
10. Exact Sciences Corporation
11. Illumina, Inc.
12. Laboratory Corporation of America Holdings
13. Lucence Health, Inc.
14. Guardant Health, Inc.
15. Sysmex Corporation
16. Agendia, Inc.
17. Paragon Genomics, Inc.
18. F. Hoffmann-La Roche Ltd.
19. HTG Molecular Diagnostics, Inc.
20. NanoString Technologies, Inc.
21. Predictive Oncology Inc.
22. IMBdx, Inc.
23. Perthera, Inc.
24. GENINUS Inc.
25. Genomic Life
26. ACT Genomics Co., Ltd. by Prenetics Global Limited
27. BostonGene Corporation
28. Caris Life Sciences
29. Strand Life Sciences
30. Neogenomics, Inc.
31. Agilent Technologies, Inc.
32. Oncompass Medicine Hungary Kft.
33. OncoDNA S.A.